ARWR
Arrowhead Pharmaceuticals Inc.

12,401
Mkt Cap
$8.68B
Volume
8.17M
52W High
$76.76
52W Low
$9.57
PE Ratio
-1,053.72
ARWR Fundamentals
Price
$70.81
Prev Close
$63.88
Open
$72.07
50D MA
$54.27
Beta
1.57
Avg. Volume
2.67M
EPS (Annual)
-$0.0122
P/B
20.62
Rev/Employee
$1.17M
Loading...
Loading...
News
all
press releases
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due...
Business Wire·8h ago
News Placeholder
More News
News Placeholder
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual key opinion leader (KOL...
MarketBeat·13h ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week High - Time to Buy?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year High - Here's What Happened...
MarketBeat·15h ago
News Placeholder
Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) saw some unusual options trading on Tuesday. Traders purchased 5,093 call options on the company. This represents an increase of...
MarketBeat·15h ago
News Placeholder
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.read more...
Benzinga·15h ago
News Placeholder
Why Did ARWR Stock Surge Over 15% Pre-Market Today?
The preliminary results from Phase 1/2a clinical trials of the company’s RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.
Stocktwits·17h ago
News Placeholder
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the companys investigational RNA interference (RNAi...
Business Wire·18h ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 13,187 Shares
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 13,187 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were...
MarketBeat·22h ago
News Placeholder
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 40,164 Shares of Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 40,164 shares of the firm's stock in a transaction dated Monday, January 5th. The stock was sold at an...
MarketBeat·1d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) COO Patrick O'brien sold 49,493 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average...
MarketBeat·1d ago
<
1
2
...
>

Latest ARWR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.